Cat:GMP-IVD-P040-Tg001
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
SKU GMP-IVD-P040-Tg001 Categories , Tag

Product Details

Genemedi produces core diagnostic ingredients for test of Infectious disease (dengue) and related syndrome. GeneMedi offers paired diagnostics grade dengue nonstructural 1 (nonstructural protein 1 (NS1)) antibodies (monoclonal antibody, mab) and antigens for Infectious disease (dengue) rapid test kit of dengue nonstructural 1 (nonstructural protein 1 (NS1)) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Infectious disease (dengue ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.D-dimer (or D dimer) is a fibrin degradation product (or FDP), a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis. It is so named because it contains two D fragments of the fibrin protein joined by a cross-link.[1] D-dimer concentration may be determined by a blood test to help diagnose thrombosis.[2] Since its introduction in the 1990s, it has become an important test performed in people with suspected thrombotic disorders, such as venous thromboembolism.[2][3] While a negative result practically rules out thrombosis, a positive result can indicate thrombosis, but does not exclude other potential causes.[3] Its main use, therefore, is to exclude thromboembolic disease where the probability is low.[1][2] D-dimer levels are used as a predictive biomarker for the blood disorder, disseminated intravascular coagulation and in the coagulation disorders associated with COVID-19 infection.[1][3] A four-fold increase in the protein is an indicator of poor prognosis in people hospitalized with COVID-19.

Product Description

Cat No. of Pruducts

GMP-IVD-P040-Tg001-Ag01:Recombinant dengue nonstructural 1 (DEN-NS1) nonstructural protein 1 (NS1) Protein

Product Name

Recombinant dengue nonstructural 1 (DEN-NS1) nonstructural protein 1 (NS1) Protein

Target

dengue nonstructural 1

Alias of Target/Biomarker

#N/A

Expression platform

E.coli

Isotypes

Recombinant Antigen

Bioactivity validation

dengue nonstructural 1 (nonstructural protein 1 (NS1)) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in nonstructural protein 1 (NS1) level test of Infectious disease (dengue) and related syndrome evaluation

Tag

His

Products description

Recombinant dengue nonstructural 1 (DEN-NS1) nonstructural protein 1 (NS1) Protein was expressed in E.coli -based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.

Reconized/Reactive Species

dengue nonstructural 1 (DEN-NS1)

Purity

Purity: ≥95% (SDS-PAGE)

Application

Standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.

Formulation

Supplied as a 0.2 μM filtered solution of PBS,PH7.4.

Storage

Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Genemeidi Omicron Variant Products
test
Previous slide
Next slide

Cat No. of Pruducts

GMP-IVD-P040-Tg001-Ab01,GMP-IVD-P040-Tg001-Ab02:Anti-dengue nonstructural 1 (DEN-NS1) nonstructural protein 1 (NS1) mouse monoclonal antibody (mAb)

Product Name

Anti-dengue nonstructural 1 (DEN-NS1) nonstructural protein 1 (NS1) mouse monoclonal antibody (mAb)

Target

dengue nonstructural 1 (DEN-NS1)

Alias of Target/Biomarker

#N/A

Expression platform

Hybridoma

Isotypes

Mouse IgG

Bioactivity validation

dengue nonstructural 1 (DEN-NS1) dengue nonstructural 1 (nonstructural protein 1 (NS1)) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other dengue nonstructural 1 (nonstructural protein 1 (NS1)) antibodies in nonstructural protein 1 (NS1) level test of Infectious disease (dengue) and related syndrome evaluation.

Tag

mFc

Products description

Anti-dengue nonstructural 1 (DEN-NS1) nonstructural protein 1 (NS1) mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other dengue nonstructural 1 (nonstructural protein 1 (NS1)) antibodies.

Reconized/Reactive Species

dengue nonstructural 1 (DEN-NS1)

Purity

Purity: ≥95% (SDS-PAGE)

Application

ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT

Formulation

Supplied as a 0.2 μM filtered solution of PBS,PH7.4.

Storage

Store at? -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Diagnostic antibodies and antigens for cancer detection - TG, CA-125, SCC Ag, PIVKA-Ⅱ, ProGRP, Calcitonin, NSE, CA-724, HE4, CA15-3, FER, CYFRA21-1, HER2, HSP90α, S100B, CEA, AFP, sFlt-1, PSA, hEGF, TFF2, TFF3, CA199, CA50, TK1

Regardless of the advances in the cancer therapy, delayed symptoms and lack of successful diagnosis of cancer at early stage increased the death rate. Tumor-associated antigens (TAAs) and their antibodies have been identified as potential markers in cancer diagnosis and determination. TAAs and their antibodies-based detection of cancer have the advantages such as low-cost, and simple access, which attracted much attention for early cancer detection. For several reasons, tumor marker itself is typically insufficient to analyze disease conditions. Because, maximum number of markers have been produced by both normal and cancer cells. Several cancers such as anal, breast, ovaries, testicles, colon, endometrial, peritoneal, fallopian tube, gallbladder, gastric, liver, lung, neuroendocrine, pancreatic, prostate, renal, cervix, stomach and thyroid cancer, bronchopulmonary dysplasia, hepatitis, hematological malignancies, hemochromatosis, hypercalcemia, osteoporosis, Parget’s diseases and so on have been identified using specific marker. Detecting the quantity of marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.